


## PURSUIT OF BREAKTHROUGHS


Amgen is pioneering drug discovery programs for cancer treatments

**~20 TREATMENTS IN DEVELOPMENT<sup>1</sup>**




## TRANSFORMING CANCER CARE


Advancing immunotherapy by using **Bispecific T cell Engager (BiTE®)** technology, which is designed to overcome cancer cells' evasion of the immune system by engaging patients' own T cells to directly target cancer cells<sup>3-5</sup>



Investigating targeting small molecule that could bind to a **mutated form of KRAS**, an oncogene that researchers have been unable to inhibit for decades<sup>1,6,7</sup>



## SERVING PATIENTS WITH DIFFERENT CANCERS<sup>2</sup>



-  LUNG CANCER
-  PROSTATE CANCER
-  STOMACH CANCER
-  ACUTE MYELOID LEUKEMIA
-  MULTIPLE MYELOMA
-  NON-HODGKIN'S LYMPHOMA

# AMGEN®

ADVANCING ONCOLOGY AT THE SPEED OF LIFE™

## AT THE CENTER OF ONCOLOGY

Committed to developing new therapies to transform the lives of people with cancer

## BRINGING TREATMENTS TO PATIENTS FASTER



Understanding how clinical trials can be redesigned such that early evidence of treatment benefit can be used to **speed up the development of cancer treatments**



Partnering with Syapse to **more precisely match patients with clinical trials<sup>8</sup>**; and with the Lazarex Cancer Foundation to **improve access to, and minority participation in, clinical trials** for patients with cancer<sup>9</sup>

To learn more about Amgen's clinical trials, visit [www.amgentrials.com](http://www.amgentrials.com)  
For more information, follow us on  @AmgenOncology

**AMGEN®**

<sup>1</sup>The size of each section within the circle is proportional to the number of molecules in development.

We understand that the cost of and access to cancer medication is a concern for patients.

## HERE IS WHAT WE ARE DOING TO ADDRESS THESE CONCERNS...

 PRICING RESPONSIBLY

 DEVELOPING BIOSIMILARS

 DONATING

 OFFERING PATIENT SUPPORT

## REFLECTING VALUE




THERAPIES DELIVER TO PATIENTS, HEALTH SYSTEMS, AND SOCIETY



## OFFERING LOWER COST TREATMENT OPTIONS

Launched the first FDA-approved oncology therapeutic biosimilars in 2019<sup>10</sup>



**\$93 MILLION**  
WORTH OF CANCER MEDICINES

distributed through Direct Relief-partner hospitals and clinics in 18 developing countries<sup>11</sup>

**\$5.5 BILLION**  
WORTH OF AMGEN MEDICINES

to help patients gain access to therapy in the US since 2008<sup>12</sup>

To learn more, visit [amgensafetynetfoundation.com](http://amgensafetynetfoundation.com)

**AMGEN FIRST STEP™**  
reduces out-of-pocket expenses for Amgen products for eligible commercially insured patients in the US  
[amgenfirststep.com](http://amgenfirststep.com)

**AMGEN ASSIST 360™**  
offers a single point of contact to help patients find co-pay, reimbursement, and other resources  
[amgenassist360.com](http://amgenassist360.com)

**AMGEN**®  
ADVANCING ONCOLOGY  
AT THE SPEED OF LIFE™

**AMGEN IS COMMITTED TO IMPROVING  
PATIENT ACCESS AND AFFORDABILITY**

## TRANSFORMING CANCER CARE TOGETHER

Amgen is working with patient societies, providers, pathologists, and others to enhance the way cancers are diagnosed and treated

CURRENTLY, AMGEN HAS

**50+ PROGRAMS**

IN ONCOLOGY AROUND THE GLOBE<sup>13,†</sup>

Aim to develop and test scalable connected health solutions for remotely monitoring patient symptoms to **improve cancer care in rural areas** – National Cancer Institute

Collaboratively studying how **patients with multiple myeloma and their physicians make decisions** together about treatment plans – University of California - Davis

Understanding how physicians utilize **biomarker testing** and genetic information to **select appropriate treatments for patients** with non-small cell lung cancer – McKesson/US Oncology

<sup>†</sup>Value-based partnerships follow and comply with Amgen policy as well as the rules and regulations of the applicable region.

References: 1. Amgen Inc. <https://www.amgenpipeline.com/>. Accessed February 24, 2020. 2. Amgen Inc. <http://investors.amgen.com/static-files/3881af6e-720b-4a98-8f97-62796e6e92a7>. Accessed February 11, 2020. 3. Frankel SR, et al. *Curr Opin Chem Biol* 2013;17:385-392. 4. Baeuerle PA, et al. *Cancer Res* 2009;69:4941-4944. 5. Yuraszcek T, et al. *Clin Pharmacol Ther*. 2017;101:634-645. 6. Cox AD, et al. *Nat Rev Drug Discov*. 2014;13:828-851. 7. Ryan MB, et al. *Nat Rev Clin Oncol* 2018;15:709-720. 8. Amgen Inc. Press release: <https://wwwext.amgen.com/media/news-releases/2019/05/amgen-and-syapse-enter-prediction-medicine-collaboration-in-oncology/>. Accessed February 11, 2020. 9. Amgen Inc. Press release: <http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=2380160>. Accessed February 11, 2020. 10. Amgen Inc. Press release, July 19, 2019: <https://wwwext.amgen.com/media/news-releases/>. Accessed February 11, 2020. 11. Amgen Inc. Press release: <https://wwwext.amgen.com/media/news-releases/2018/12/amgen-and-direct-relief-partner-to-aid-cancer-patients-in-18-developing-countries/>. Accessed February 11, 2020. 12. Amgen Safety Net Foundation. <http://www.amgensafetynetfoundation.com/about.html>. Accessed February 11, 2020. 13. Data on file, Amgen; [Amgen VBP Handout; Q4 2019].